{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:06:34Z","timestamp":1760781994641,"version":"3.37.3"},"reference-count":57,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acquired T-cell dysfunction is common in chronic B-cell malignancies. Given the strong connection between T-cell metabolism and function, we investigated metabolic alterations as the basis of T-cell dysfunction induced by malignant cells. Using B-cell malignant cell lines and human peripheral blood mononuclear cells, we first established a model that recapitulates major aspects of cancer-induced T-cell dysfunction. Cell lines derived from chronic lymphocytic leukemia (CLL) (PGA-1, CII, and Mec-1), but not from other B-cell malignancies, altered the T-cell metabolome by generating a pseudohypoxic state. T\u00a0cells were retained in aerobic glycolysis and were not able to switch to oxidative phosphorylation (OXPHOS). Moreover, T cells produced immunosuppressive adenosine that negatively affected function by dampening the activation, which could be restored by the blocking of adenosine receptors. Subsequently, we uncovered a similar hypoxic-like signature in autologous T cells from primary CLL samples. Pseudohypoxia was reversible upon depletion of CLL cells ex\u00a0vivo and, importantly, after the in\u00a0vivo reduction of the leukemic burden with combination therapy (venetoclax and obinutuzumab), restoring T-cell function. In conclusion, we uncovered a pseudohypoxic program connected with T-cell dysfunction in CLL. Modulation of hypoxia and the purinergic pathway might contribute to therapeutic restoration of T-cell function.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010305","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T14:05:27Z","timestamp":1691503527000},"page":"6540-6552","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0753-231X","authenticated-orcid":false,"given":"Chiara","family":"Montironi","sequence":"first","affiliation":[{"name":"1Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"},{"name":"3Cancer Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaja F.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"1Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"},{"name":"3Cancer Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"4Department of Hematology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaspard","family":"Cretenet","sequence":"additional","affiliation":[{"name":"1Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"},{"name":"3Cancer Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"4Department of Hematology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-315X","authenticated-orcid":false,"given":"Fleur S.","family":"Peters","sequence":"additional","affiliation":[{"name":"1Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"},{"name":"3Cancer Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"4Department of Hematology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bauke V.","family":"Schomakers","sequence":"additional","affiliation":[{"name":"5Laboratory Genetic Metabolic Diseases, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"6Core Facility Metabolomics, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-2866","authenticated-orcid":false,"given":"Michel","family":"van Weeghel","sequence":"additional","affiliation":[{"name":"5Laboratory Genetic Metabolic Diseases, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"6Core Facility Metabolomics, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"1Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"},{"name":"3Cancer Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"4Department of Hematology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-6133","authenticated-orcid":false,"given":"Helga","family":"Simon-Molas","sequence":"additional","affiliation":[{"name":"1Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"},{"name":"3Cancer Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"4Department of Hematology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-6640","authenticated-orcid":false,"given":"Eric","family":"Eldering","sequence":"additional","affiliation":[{"name":"1Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"},{"name":"3Cancer Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"issue":"1","key":"2023111414505466000_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","article-title":"Unraveling the complex interplay between T cell metabolism and function","volume":"36","author":"Geltink","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"2023111414505466000_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cytogfr.2017.04.003","article-title":"Dysfunctional T cell metabolism in the tumor microenvironment","volume":"35","author":"Beckermann","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"2023111414505466000_bib3","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T\u00a0cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"2023111414505466000_bib4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"8","key":"2023111414505466000_bib5","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cmet.2022.06.008","article-title":"Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells","volume":"34","author":"Elia","year":"2022","journal-title":"Cell Metab"},{"issue":"6614","key":"2023111414505466000_bib6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.abj5104","article-title":"Oncometabolite d-2HG alters T cell metabolism to impair CD8\u00a0+ T cell function","volume":"377","author":"Notarangelo","year":"2022","journal-title":"Science"},{"key":"2023111414505466000_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2018.00353","article-title":"Targeting tumor metabolism: a new challenge to improve immunotherapy","volume":"9","author":"Kouidhi","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2023111414505466000_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-020-02667-4","article-title":"Hypoxia and the phenomenon of immune exclusion","volume":"19","author":"Pietrobon","year":"2021","journal-title":"J\u00a0Transl Med"},{"issue":"4","key":"2023111414505466000_bib9","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1159\/000464429","article-title":"Hypoxia enhances immunosuppression by inhibiting CD4+ effector T cell function and promoting Treg activity","volume":"41","author":"Westendorf","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"2023111414505466000_bib10","doi-asserted-by":"crossref","first-page":"e56612","DOI":"10.7554\/eLife.56612","article-title":"Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest","volume":"9","author":"Saragovi","year":"2020","journal-title":"Elife"},{"key":"2023111414505466000_bib11","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist Updat"},{"key":"2023111414505466000_bib12","first-page":"131","volume-title":"Advances in Experimental Medicine and Biology","author":"Multhoff","year":"2020"},{"key":"2023111414505466000_bib13","doi-asserted-by":"crossref","first-page":"570041","DOI":"10.3389\/fimmu.2020.570041","article-title":"Targeting hypoxia-A2A adenosinergic immunosuppression of antitumor T cells during cancer immunotherapy","volume":"11","author":"Steingold","year":"2020","journal-title":"Front Immunol"},{"issue":"16","key":"2023111414505466000_bib14","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1158\/1078-0432.CCR-06-2510","article-title":"Pseudohypoxic pathways in renal cell carcinoma","volume":"13","author":"Bratslavsky","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2023111414505466000_bib15","doi-asserted-by":"crossref","first-page":"594556","DOI":"10.3389\/fimmu.2020.594556","article-title":"Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia","volume":"11","author":"Griggio","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"2023111414505466000_bib16","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1541-7786.MCR-14-0028","article-title":"The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies","volume":"12","author":"Muz","year":"2014","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2023111414505466000_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2016000984","article-title":"Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment","volume":"1","author":"Serra","year":"2016","journal-title":"Blood Adv"},{"key":"2023111414505466000_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2016.00041","article-title":"Hypoxia and hypoxia-inducible factors in leukemias","volume":"6","author":"Deynoux","year":"2016","journal-title":"Front Oncol"},{"issue":"1","key":"2023111414505466000_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy","volume":"134","author":"Van Bruggen","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2023111414505466000_bib20","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","article-title":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","volume":"9","author":"Kersting","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"2023111414505466000_bib21","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2023111414505466000_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease","volume":"365","author":"Semenza","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023111414505466000_bib23","doi-asserted-by":"crossref","first-page":"C580","DOI":"10.1152\/ajpcell.00204.2015","article-title":"Hypoxia-inducible factors in T lymphocyte differentiation and function. A review in the theme: cellular responses to hypoxia","volume":"309","author":"Tao","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"issue":"12","key":"2023111414505466000_bib24","doi-asserted-by":"crossref","first-page":"7592","DOI":"10.4049\/jimmunol.174.12.7592","article-title":"TCR engagement increases hypoxia-inducible factor-1\u03b1 protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells","volume":"174","author":"Nakamura","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"2023111414505466000_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccell.2017.10.003","article-title":"An HIF-1\u03b1\/VEGF-A axis in cytotoxic T cells regulates tumor progression","volume":"32","author":"Palazon","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2023111414505466000_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40170-017-0165-0","article-title":"The \u03b1-ketoglutarate dehydrogenase complex in cancer metabolic plasticity","volume":"5","author":"Vatrinet","year":"2017","journal-title":"Cancer Metab"},{"issue":"1","key":"2023111414505466000_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","article-title":"NAD+ metabolism, stemness, the immune response, and cancer","volume":"6","author":"Navas","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2023111414505466000_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-Cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"2023111414505466000_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00109-012-0988-7","article-title":"Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease","volume":"91","author":"Poth","year":"2013","journal-title":"J\u00a0Mol Med"},{"issue":"6","key":"2023111414505466000_bib30","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"1-2","key":"2023111414505466000_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jim.2011.04.004","article-title":"Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets","volume":"369","author":"Schuler","year":"2011","journal-title":"J\u00a0Immunol Methods"},{"issue":"3","key":"2023111414505466000_bib32","first-page":"243","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2023111414505466000_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1203\/00006450-198802000-00001","article-title":"Hypoxanthine as an indicator of hypoxia: its role in health and disease through free radical production","volume":"23","author":"Saugstad","year":"1988","journal-title":"Pediatr Res"},{"issue":"7","key":"2023111414505466000_bib34","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023111414505466000_bib35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3324\/haematol.2020.267914","article-title":"T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective","volume":"106","author":"Peters","year":"2021","journal-title":"Haematologica"},{"issue":"14","key":"2023111414505466000_bib36","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2022007034","article-title":"Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4\u00a0T cells","volume":"6","author":"van Bruggen","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"2023111414505466000_bib37","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1084\/jem.20112607","article-title":"PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T\u00a0cells","volume":"209","author":"Finlay","year":"2012","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"2023111414505466000_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol Med"},{"issue":"8","key":"2023111414505466000_bib39","doi-asserted-by":"crossref","first-page":"1939-1923","DOI":"10.3390\/biomedicines10081939","article-title":"The hypoxia-adenosine link during myocardial ischemia\u2014reperfusion injury","volume":"10","author":"Ruan","year":"2022","journal-title":"Biomedicines"},{"key":"2023111414505466000_bib40","doi-asserted-by":"crossref","first-page":"604944","DOI":"10.3389\/fimmu.2020.604944","article-title":"Adenosine at the interphase of hypoxia and inflammation in lung injury","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2023111414505466000_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cmet.2021.12.009","article-title":"A\u00a0purine metabolic checkpoint that prevents autoimmunity and autoinflammation","volume":"34","author":"Saveljeva","year":"2022","journal-title":"Cell Metab"},{"issue":"16","key":"2023111414505466000_bib42","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1111\/febs.15327","article-title":"Glycolysis \u2013 a key player in the inflammatory response","volume":"287","author":"Soto-Heredero","year":"2020","journal-title":"FEBS J"},{"issue":"8","key":"2023111414505466000_bib43","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00277-012-1425-2","article-title":"Increased CD39 expression on CD4\u00a0+ T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia","volume":"91","author":"Perry","year":"2012","journal-title":"Ann Hematol"},{"key":"2023111414505466000_bib44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.taap.2016.11.016","article-title":"Protective role of hypoxia-inducible factor-1\u03b1-dependent CD39 and CD73 in fulminant acute liver failure","volume":"314","author":"Tak","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"2023111414505466000_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood-2008-06-165746","article-title":"Central role of Sp1-regulated CD39 in hypoxia\/ischemia protection","volume":"113","author":"Eltzschig","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2023111414505466000_bib46","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2023111414505466000_bib47","first-page":"1","article-title":"\u57fa\u56e0\u7684\u6539\u53d8NIH public access","volume":"23","author":"Range","year":"2012","journal-title":"Bone"},{"issue":"2","key":"2023111414505466000_bib48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41590-022-01379-9","article-title":"Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity","volume":"24","author":"Vignali","year":"2023","journal-title":"Nat Immunol"},{"issue":"2","key":"2023111414505466000_bib49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat Immunol"},{"issue":"2","key":"2023111414505466000_bib50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10555-007-9054-2","article-title":"Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues","volume":"26","author":"Lukashev","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"2023111414505466000_bib51","doi-asserted-by":"crossref","first-page":"111193","DOI":"10.1016\/j.celrep.2022.111193","article-title":"Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation","volume":"40","author":"Gudgeon","year":"2022","journal-title":"Cell Rep"},{"issue":"9","key":"2023111414505466000_bib52","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1371\/journal.pone.0000853","article-title":"Targeted deletion of HIF-1\u03b1 gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival","volume":"2","author":"Thiel","year":"2007","journal-title":"PLoS One"},{"issue":"12","key":"2023111414505466000_bib53","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","article-title":"Impact of the selective A2AR and A2BR dual antagonist AB928\/etrumadenant on CAR T cell function","volume":"127","author":"Seifert","year":"2022","journal-title":"Br J Cancer"},{"issue":"8","key":"2023111414505466000_bib54","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep"},{"issue":"28","key":"2023111414505466000_bib55","doi-asserted-by":"crossref","first-page":"9551","DOI":"10.1074\/jbc.RA119.012175","article-title":"Hypoxia drives the assembly of the multienzyme purinosome complex","volume":"295","author":"Doigneaux","year":"2020","journal-title":"J\u00a0Biol Chem"},{"key":"2023111414505466000_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/ijms21239281","article-title":"Guanosine-mediated anxiolytic-like effect: interplay with adenosine A1 and A2A receptors","volume":"21","author":"Frinchi","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2023111414505466000_bib57","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11302-020-09723-0","article-title":"Guanosine modulates SUMO2\/3-ylation in neurons and astrocytes via adenosine receptors","volume":"16","author":"Zanella","year":"2020","journal-title":"Purinergic Signal"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6540\/2089113\/blooda_adv-2023-010305-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6540\/2089113\/blooda_adv-2023-010305-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:52:35Z","timestamp":1699973555000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6540\/497366\/T-cell-dysfunction-by-pseudohypoxia-and-autocrine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":57,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010305","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}